The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Response criteria for intratumoral immunotherapy in solid tumors: ItRECIST.
 
Gregory V. Goldmacher
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Beta Bionics; Merck Sharp & Dohme
 
Anuradha D. Khilnani
Employment - Merck
Honoraria - Eisai; Pfizer
Consulting or Advisory Role - Eisai
Travel, Accommodations, Expenses - Merck
 
Robert H. I. Andtbacka
Employment - Merck Sharp & Dohme (I); Novartis (I); Seven and Eight Biopharmaceuticals
Stock and Other Ownership Interests - Merck Sharp & Dohme (I); Novartis (I)
Honoraria - Novartis
Consulting or Advisory Role - Merck/Schering Plough; Novartis; Pfizer
Research Funding - Amgen (Inst); Idera (Inst); Oncolys BioPharma (Inst); OncoSec (Inst); Provectus (Inst); Takara Bio (Inst); Viralytics (Inst); X4 Pharma (Inst)
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Kanaph Therapeutics; Mavu Pharmaceutical; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Actym Therapeutics; Aduro Biotech; Akrevia Therapeutics; Alphamab; Amgen; Array BioPharma; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Benevir; Bristol-Myers Squibb; Compugen; Eisai; EMD Serono; IDEAYA Biosciences; Immunocore; Incyte; Janssen; Jounce Therapeutics; Leap Therapeutics; Mavu Pharmaceutical; Merck; Mersana; Novartis; Partner Therapeutics; Reflexion Medical; Spring Bank; Synlogic; Tempest Therapeutics; TTC Oncology; Vividion Therapeutics
Research Funding - Abbvie (Inst); Array BioPharma; Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Checkmate Pharmaceuticals; Compugen (Inst); Corvus Pharmaceuticals (Inst); Delcath Systems (Inst); Evelo Therapeutics; Five Prime Therapeutics (Inst); FLX Bio; Genentech/Roche (Inst); Immunocore (Inst); Incyte (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Palleon Pharmaceuticals; Pharmacyclics (Inst); Tesaro (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Akrevia Therapeutics; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Immunocore; Janssen; Jounce Therapeutics; Merck; Mersana; Novartis; Reflexion Medical
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health; Torque
Consulting or Advisory Role - 7 Hills Pharma; Aduro Biotech; Amgen; Bayer; Boston Pharmaceuticals; Bristol-Myers Squibb; Compass Therapeutics; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis; Partners Therapeutics; Pfizer; Pionyr; Rheos Medicines; Sanofi; Surface Oncology; Takeda; Torque; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Aurelien Marabelle
Stock and Other Ownership Interests - PEGASCY
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merieux Nutrisciences; Oncovir
Consulting or Advisory Role - AMGEN; AstraZeneca; Bayer; Bioncotech; Boehringer Ingelheim; CERENIS THERAPEUTICS; Eisai; Gritstone Bio; ImCheck therapeutics; Innate Pharma; Lytix Biopharma; Merck Serono; Molecular Partners; MSD; NOVARTIS; OSE Immunotherapeutics; Partner Therapeutics; Pfizer; Pfizer; Pierre Fabre; Redx Pharma; Roche; Sanofi; SERVIER; Sotio; Symphogen
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MERUS (Inst); MSD (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Other Relationship - PEGASCY
 
Kevin Joseph Harrington
Honoraria - Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Oncolys BioPharma (Inst); Pfizer (Inst); Replimune (Inst)
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Replimune (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck Sharp & Dohme (Inst); Replimune (Inst)
 
Andrea Marie Perrone
Employment - Merck
Stock and Other Ownership Interests - Merck Sharp & Dohme
Other Relationship - University of Pennsylvania (I)
 
Archie N. Tse
Employment - CStone Pharmaceuticals
Leadership - CStone Pharmaceuticals
Stock and Other Ownership Interests - CStone Pharmaceuticals
 
David C. Madoff
Honoraria - Penumbra
Consulting or Advisory Role - GE Healthcare; Merck; Quantum Surgical
 
Lawrence Howard Schwartz
Consulting or Advisory Role - Novartis; Regeneron
Research Funding - Boehringer Ingelheim (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Varian Medical Systems